Taiwanese continual illness administration firm Health2Sync has entered right into a partnership with Danish pharmaceutical agency Novo Nordisk to assist sufferers present process insulin remedy wirelessly switch dose logs to a cellular well being app.
The Health2Sync cellular app is now in a position to sync sufferers’ dose logs, together with time and dosage per injection, from the newly launched NovoPen 6 and NovoPen Echo Plus which were powered by near-field communication.
This integration permits customers to browse insulin readings and evaluation, together with different well being information, on the Health2Sync app, whereas clinicians can view their insulin information on the Affected person Administration Platform.
The partnership additionally initiates a affected person help programme, which creates tailor-made and age-based instructional content material for sufferers with Sort 1 diabetes (T1D). These content material embrace details about their illness, use of insulin, consideration wanted throughout seasonal adjustments, and methods to cope with opposed well being situations, in addition to experiences shared by different Sort 1 sufferers.
WHY IT MATTERS
A century since insulin, a hormone that permits the human physique to make use of glucose, was found, Health2Sync famous that one in two sufferers with sort 2 diabetes is just not getting handled whereas the variety of sufferers requiring insulin therapy nonetheless attain between 150-200 million globally.
By way of a brand new help programme and by enabling the combination of good insulin pens with the Health2Sync app, “sufferers receiving insulin remedy can attain optimum glucose management with the assistance of the improved communication and training offered,” stated Ed Deng, CEO and co-founder of Health2Sync.
Takatsugu Den, director of the Diabetes and Weight problems Enterprise at Novo Nordisk Pharma, stated they anticipate that by means of age-based instructional content material, which incorporates manga and animation, “kids and adolescents with T1D can receive therapy info extra simply and that beginning insulin therapy will turn out to be easier and simpler to regulate to”.
For now, the service is on the market for Japanese sufferers with plans to introduce it to “different markets within the area,” Deng shared.
THE LARGER TREND
Health2Sync’s newest collaboration with a multinational drugmaker follows one other partnership with French pharma firm Sanofi that was signed in December final 12 months. Sanofi will assist Health2Sync in rolling out its upcoming insulin administration answer, which is being constructed with titration algorithms to facilitate efficient coordination between healthcare suppliers and sufferers.
In the meantime in November final 12 months, Health2Sync launched an up to date model of its cellular app in Japan that was made to combine steady glucose monitoring information from the Abbott FreeStyle LibreLink cellular app. The newest app permits them to view their CGM information, together with figures on their weight-reduction plan, weight, blood stress, and train information captured from Fitbit.